CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated C...(ase in women who arepregnant or may beco...),Health

Date:11/9/2007

ase, in women who are pregnant or may become pregnant, and in nursing mothers. Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with drugs in this class, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir. Combination therapy with rosuvastatin and gemfibrozil should be avoided. CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy, such as renal impairment, advanced age, and inadequately treated hypothyroidism. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver function tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. CRESTOR is generally well-tolerated. The most frequent adverse reactions thought to be related to CRESTOR were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees. For nearly thr
'/>"/>

SOURCE AstraZeneca Copyright©2007 PR Newswire. All rights reserved

4 GOOD

Page: 1 2 3 4
Related medicine news :

1. Brain Lesions Predict MS Progression
2. Pregnancy may slow -- not accelerate -- progression to AIDS
3. Progression of SIV infection in monkeys raises
4. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
5. Limiting refined carbohydrates may stall AMD progression
6. New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years
7. Study finds genetic influence on pace of HIV/AIDS progression
8. Lifetime trauma may speed progression of HIV, early death
9. A new mathematical formula for cancer progression
10. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
11. Comparison of obstetric outcomes between on-call and patients own obstetricians